COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
(Albany, USA) DelveInsight’s Glioblastoma Multiforme Market Insights report includes a comprehensive understanding of current treatment practices, glioblastoma multiforme emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
To know more about the Glioblastoma Multiforme Market Report offerings, click here @ Glioblastoma Multiforme Market Forecast
Key Takeaways from the Glioblastoma Multiforme Market Report
Discover which therapies are expected to grab the major glioblastoma multiforme market share @ https://www.delveinsight.com/sample-request/glioblastoma-market
Glioblastoma Multiforme Overview
Glioblastoma, also known as glioblastoma multiforme is cancer that can develop in the brain or spinal cord. Glioblastoma develops from astrocytes, which are nerve cell-feeding cells. It can occur at any age, but it is more common in the elderly. It can make headaches, nausea, vomiting, and seizures worse. The causes of glioblastoma are unknown.
Glioblastoma symptoms vary depending on tumor type, size, location, and growth rate. Headache, nausea or vomiting, confusion or deterioration in brain function, memory loss, personality changes or irritability, and difficulty balancing are all common glioblastoma symptoms. Computed tomography (CT or CAT scan) and magnetic resonance imaging (MRI) are two diagnostic tools used for glioblastoma diagnosis. Glioblastoma treatments may slow cancer progression and alleviate symptoms.
Glioblastoma Multiforme Epidemiology Segmentation
DelveInsight estimates that there were approximately 32.5K incident cases of glioblastoma multiforme in the 7MM in 2021.
Among the EU-4 countries, the incident population of GBM was found to be the maximum in Germany in 2021.
The glioblastoma multiforme market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Download the report to understand which factors are driving glioblastoma multiforme epidemiology trends @ https://www.delveinsight.com/sample-request/glioblastoma-market
Glioblastoma Multiforme Treatment Market
Glioblastoma multiforme is typically treated with a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Although rarely used alone, surgery is usually one of the most important aspects of glioblastoma treatment. Because glioblastomas grow so quickly, they are frequently difficult to remove completely. As a result, surgery is performed to achieve the best possible safe resection – removing as much of the tumor as possible while preserving brain function and sparing healthy tissues. Following surgery, residual cancer cells can be targeted with additional treatments such as chemotherapy or radiation therapy. Once the tumor’s diagnosis or name is determined, radiation therapy and chemotherapy are usually administered.
These are known as adjuvant glioblastoma treatments. Because this multispecialty approach can have several side effects, steroids are frequently used as an additional component of glioblastoma treatment to help alleviate the side effects of other therapies.
Chemotherapy is a common type of glioblastoma treatment. Patients typically begin chemotherapy 2-4 weeks after surgery, at the same time as or shortly after radiation therapy. When a tumor cannot be surgically removed, chemotherapy is sometimes used as the primary glioblastoma treatment.
Cytotoxic drugs include Carmustine (BCNU), Lomustine (CCNU), or Gleostine (Generic), Gliadel wafer (biodegradable discs infused with BCNU), Temozolomide (Temodar), Cisplatin, Carboplatin, Etoposide, and Irinotecan.
To know more about glioblastoma treatment options, visit @ https://www.delveinsight.com/sample-request/glioblastoma-market
Glioblastoma Multiforme Pipeline Therapies and Key Companies
Learn more about the glioblastoma FDA-approved drugs @ https://www.delveinsight.com/sample-request/glioblastoma-market
Scope of the Glioblastoma Multiforme Market Report
Discover more about glioblastoma drugs in development @ https://www.delveinsight.com/sample-request/glioblastoma-market
Table of Contents
1 Key Insights
2 Report Introduction
3 Glioblastoma Multiforme Market Overview at a Glance
3.1 Market Share (%) Distribution of GBM in 2019 by Countries
3.2 Market Share (%) Distribution of GBM in 2032 by Countries
4 Epidemiology and Market Forecast Methodology
5 Executive Summary of Glioblastoma Multiforme (GBM)
6 Key Events
7 SWOT Analysis
8 Disease Background and Overview: Glioblastoma Multiforme
8.1 Introduction
8.2 Classification of Glioblastoma Multiforme
8.3 Glioblastoma Types
8.4 Symptoms
8.5 Pathophysiology
8.6 Inheritance of Glioblastoma Multiforme
8.7 Molecular Classification
8.8 Diagnosis of Glioblastoma Multiforme
9 Treatment
10 Guidelines and Recommendations from Different Organizations
11 Epidemiology and Patient Population
12 Patient Journey
13 Key Endpoints in Glioblastoma Multiforme
14 Marketed Products
14.1 Key Competitors
15 Emerging Drugs
15.1 Key Competitors
16 GBM: Seven Major Market Analysis
17 KOL Views
18 Unmet Needs
19 Market Access and Reimbursement
20 Appendix
20.1 Bibliography
20.2 Report Methodology
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight
Discover more about glioblastoma drugs in development @ https://www.delveinsight.com/sample-request/glioblastoma-market
New Reports Launched:
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting